Insulin and diabetes drugs pull glucose out of the blood and out of the cells, producing an internal 'famine'.
Original statement
الأنسولين وأدوية السكر تسحب السكر من الدم والخلايا، فتسبب «مجاعة» داخل الجسم
not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.
Translation
Insulin and diabetes drugs pull glucose out of the blood and out of the cells, producing an internal 'famine'.
Origin
- Source status
- Archive quote (no location given)
- Attribution
- Elawady (archive paraphrase; source video not given)
- Origin
- https://eltayebat.com/rule/oral-diabetes-drugs/
- Attribution uncertainty
- The archive attributes this text to Dr. Diaa in its 'د. ضياء يقول' box but gives no video reference. Transcript check (the project's research files, keyword search of 307 archive transcripts): similar_idea_only. The image of an 'internal famine' (مجاعة) was found in his transcripts only in other contexts (fasting, war), not in relation to insulin or diabetes drugs. A passage stating that anyone who lowers blood sugar or takes insulin, Galvus, Forxiga or Mounjaro will be harmed (5Pr4BCDlQeI) expresses a related idea.
- Claimed mechanism
Glucose-lowering drugs deprive cells of fuel.
- Claimed health effect
Cell starvation
- Population concerned
People taking glucose-lowering drugs
- Geographic restriction by Elawady
none found
Diverging source versions
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr Diaa Al Awady د ضياء العوضي is live!فلسفة الصيام مع السحور المحترم (Open source)
- Published
- 23 February 2026
- Timestamp
- not available (transcript has no timings)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
اللي هيوطي السكر هيتفشخ اللي هياخد انسولين هيتفشخ اللي هياخد دوا جالفس هيتفشخ اللي هياخد فورسيجا هيتفشخ اللي هياخد مونجارو هيتفشخ
Whoever lowers the sugar will be wrecked; whoever takes insulin will be wrecked; whoever takes the drug Galvus will be wrecked; whoever takes Forxiga will be wrecked; whoever takes Mounjaro will be wrecked (vulgar colloquial verb).
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- بدأت قناة ＂Dr Diaa Al Awady د ضياء العوضي＂ بثًا مباشرًا ذكري يوم ميلادي 😂😂❤️❤️❤️ (Open source)
- Published
- 26 March 2026
- Timestamp
- 1:16:57 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; YouTube original not checked; wording may contain recognition errors. Similar idea only; the 'famine' image is not in this passage.
Scientific assessment
Mostly false – Essential parts of the statement are not supported by the evidence or are strongly exaggerated.
Certainty of evidence: high – Further research is very unlikely to change the assessment.
1. What was claimed?
Diabetes drugs starve the body by removing glucose from blood and cells.
2. What is demonstrably correct?
Insulin and sulfonylureas can cause hypoglycaemia, which deprives the brain of glucose; this is the main harm of over-treatment (A-INS-14, A-INS-15, A-INS-16). Trials of intensive glucose lowering roughly doubled to tripled severe hypoglycaemia (HR 2.48, 1.91-3.21) without reducing mortality (I-ODD-108), and in ACCORD targeting near-normal HbA1c in high-risk type 2 diabetes increased mortality (257 vs 203 deaths; HR 1.22, 1.01-1.46) (A-INS-01). This is why guidelines individualise targets (I-INS-10). SGLT2 inhibitors can cause a starvation-like ketotic state in some situations (I-ODD-10).
3. What is wrong or exaggerated?
In hyperglycaemia the problem is not lack of glucose in the blood but too much; insulin moves glucose into muscle and fat cells where it is used or stored, so cells are not starved. Insulin deficiency, not insulin, produces an internal 'famine' with breakdown of fat and muscle (I-INS-08).
4. What remains unclear?
No study has tested an 'internal famine' concept because it is not a defined physiological state. The archive's wording ('internal famine') was found in Elawady's transcripts only in other contexts (fasting, war), so it is uncertain whether he used this image for insulin.
5. Which studies support it?
None for an 'internal famine'. Mixed: A-INS-14, A-INS-15 (hypoglycaemia kernel only; hypoglycaemia uncommon and mostly a marker of vulnerability), I-ODD-10.
6. Which studies contradict it?
I-INS-08 (insulin deficiency causes the catabolic state), I-INS-03 and I-INS-104 (intensive insulin therapy in type 1 diabetes lowered mortality over 27 years: HR 0.67, 0.46-0.99), I-INS-134 (NICE NG17), I-ODD-16 (ADA 2026: insulin essential in type 1 diabetes).
7. What applies to Germany and Europe?
European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.
8. What is known about Egypt?
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
9. What practical conclusion is appropriate?
Hypoglycaemia is a real risk that requires dose adjustment and education; it is not a general property of diabetes treatment.
Assessment details
- Rationale for certainty of evidence
Glucose-lowering drugs act by increasing glucose uptake into tissues (insulin), reducing hepatic glucose output (metformin), or excreting excess glucose (SGLT2). Only overdose/hypoglycaemia deprives the brain of glucose. The 'famine' concept has no empirical support apart from that kernel.
- Source quality
Archive paraphrase plus own words.
- Regional transferability
Universal.
- Individual exceptions
Older or frail people and those on insulin/sulfonylureas are at higher hypoglycaemia risk.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 26 October 2026 provisional
Scientific evidence in detail
Scientifically refuted – High-quality evidence shows the opposite, or the claim contradicts well-established physiology.
Research question: Do insulin and other glucose-lowering drugs deprive cells of glucose ('internal famine'), and what is the actual effect of glucose-lowering treatment on cellular fuel supply, hypoglycaemia and mortality?
Research question in detail (PICO)
- Population
- People with type 1 or type 2 diabetes
- Intervention or exposure
- Insulin and other glucose-lowering drugs (standard or intensive use)
- Comparison
- No/less intensive treatment
- Geographic scope
- universal biology
- Outcomes
- Severe hypoglycaemia
- All-cause mortality
- DKA / catabolic state from insulin deficiency
Study results as reported by the authors. Our assessment follows below.
What speaks for the claim?
Very aggressive blood sugar lowering in high-risk type 2 diabetes
Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743 Randomised controlled trialfull text checkedACCORD: targeting near-normal HbA1c with intensive therapy increased mortality and severe hypoglycaemia in high-risk type 2 diabetes.
- Actual result
- Deaths 257 vs 203; HR 1.22 (1.01-1.46); trial stopped early.
- Methodological quality
- high (large RCT)
- Relevance
- indirect - shows harm of over-intensive lowering, not cellular starvation
- Limitations
- Mechanism of excess deaths unclear; older drug strategies.
Very tight sugar control: fewer heart attacks, more severe low sugars
Control Group (Turnbull FM et al.). Diabetologia 2009 · PMID 19655124 · DOI 10.1007/s00125-009-1470-0 Meta-analysisabstract checkednewly addedMeta-analysis of intensive-control trials: severe hypoglycaemia about 2.5-fold higher; mortality unchanged.
- Actual result
- Major hypoglycaemia HR 2.48 (1.91-3.21); death HR 1.04 (0.90-1.20); MI HR 0.85.
- Methodological quality
- high
- Relevance
- indirect
- Limitations
- Group-level data.
What speaks against the claim?
Long-term survival after intensive insulin treatment in type 1 diabetes
Writing Group for the DCCT/EDIC Research Group et al.. JAMA 2015 · PMID 25562265 · DOI 10.1001/jama.2014.16107 Randomised controlled trialabstract checkednewly addedDCCT/EDIC: intensive insulin therapy in type 1 diabetes lowered mortality over 27 years.
- Actual result
- HR 0.67 (0.46-0.99); -109 deaths per 100,000 patient-years.
- Methodological quality
- high (randomised origin, long follow-up)
- Relevance
- direct for insulin
- Limitations
- Borderline precision.
Review on diabetic ketoacidosis
Dhatariya KK et al.. Nat Rev Dis Primers 2020 · PMID 32409703 · DOI 10.1038/s41572-020-0165-1 Narrative reviewfull text, structured risk-of-bias assessmentDKA review: insulin deficiency, not insulin, produces the catabolic, starvation-like state with fat breakdown and ketoacidosis.
- Actual result
- Narrative review (Nat Rev Dis Primers).
- Methodological quality
- moderate (expert review of established physiology)
- Relevance
- direct for mechanism
- Limitations
- Narrative.
What does the overall evidence say?
Editorial assessment based on the studies above – not itself a study result.
Which position is better supported?
Insulin moves glucose from the blood into muscle and fat cells; it does not pull glucose out of cells. The starvation-like state ('famine') in diabetes is caused by insulin deficiency, which leads to DKA. The true kernel is that excessive glucose lowering, mainly with insulin or sulfonylureas, can cause hypoglycaemia and, in ACCORD, aggressive near-normal targets increased mortality; this is why targets are individualised.
Why some studies weigh more
Physiology and RCTs (DCCT/EDIC, ACCORD, meta-analysis) outweigh the image of 'famine', which has no empirical basis beyond hypoglycaemia.
Is a causal relationship established? Yes, established Causality is established for hypoglycaemia from overdosing and for harm from over-intensive targets in high-risk patients; a general cellular famine from glucose-lowering drugs is incompatible with established physiology.
Remaining uncertainty
Mechanisms of excess mortality in ACCORD.
Justified conclusion
The claim is mostly false; only over-treatment causing hypoglycaemia is a real, managed risk. Stopping insulin is dangerous.
Why do studies seem to disagree?
ACCORD (harm) and DCCT/EDIC or UKPDS follow-up (benefit) answer different questions: ACCORD tested very aggressive targets in older high-risk type 2 patients with older drugs; DCCT/UKPDS tested moderate intensification earlier in disease. Both support individualised targets, neither supports avoiding glucose-lowering treatment.
Does this depend on the country?
- General biological effects
- Drug pharmacology and physiology are universal.
- Eating habits
- Prolonged fasting, Ramadan fasting and very-low-carbohydrate eating change the risk of hypoglycaemia and ketoacidosis with some drugs; relevant in Egypt and among Muslims in Europe.
- Origin of the food
- Not applicable.
- Contaminants
- Not applicable.
- National production conditions
- Not applicable (same active substances; generics widely used in Egypt).
- Legal rules
- Drug labels and warnings are set by FDA/EMA and national regulators; Egyptian labelling not reviewed.
- Actual monitoring data
- No Egypt-specific pharmacovigilance data were found for this outcome.
A regional difference that changes the conclusion is not supported by robust data.
Statistical re-check
- Approximate absolute mortality increase – 5.01% vs 3.96% assuming equal arm sizes (arm sizes not in abstract): +1.05 percentage points, NNH about 95 over 3.5 years. recalculated
- CI symmetry – All HRs symmetric on log scale. recalculated
- Absolute benefit – 1 death prevented per about 917 patient-years; about 2.9 fewer deaths per 100 over 27 years. recalculated
Certainty of the overall evidence (GRADE, simplified)
- Main outcome
- Cellular fuel deprivation ('famine') from glucose-lowering drugs vs physiological effect and mortality
- Starting level
- high (randomised trials)
- Reasons for downgrading
- indirectness: no study tests 'famine' as such; judged on physiology and outcome trials
- Result
- high
Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.
Clinical guidelines and official statements checked
- ADA: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (Diabetes Care 2026;49 Suppl 1) (2026) · Original publication
Insulin treatment is essential for type 1 diabetes; insulinopenia contributes to ketoacidosis and life-threatening catabolism (rec. 9.1). - ADA: 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026) · Original publication
ACCORD stopped early for higher mortality with intensive glucose lowering; select individual goals that avoid hypoglycaemia; people on intensive insulin should not stop basal insulin even if not eating. - NICE: Type 1 diabetes in adults: diagnosis and management (NG17), last updated 17 August 2022 (2022) · Original publication
Insulin regimens for all adults with type 1 diabetes; sick-day rules to adjust insulin during illness; ketone monitoring to prevent DKA.
Search strategy
Documented literature searches for this review (search strings in the original database syntax).
| Database | Date | Search | Looking for | Hits | Included |
|---|---|---|---|---|---|
| PubMed | 26 October 2026 | ("intensive glycaemic control"[tiab] OR "intensive glycemic control"[tiab] OR "intensive glucose"[tiab]) AND (mortality[tiab] OR hypoglycaemia[tiab] OR hypoglycemia[tiab]) AND ("Cochrane Database Syst Rev"[ta] OR meta-analysis[pt]) | supporting evidence | 50 | |
| Europe PMC | 26 October 2026 | ("intensive treatment" OR "intensive therapy") AND "type 1 diabetes" AND mortality AND (DCCT OR EDIC) | contradicting evidence | 803 | |
| PubMed | 26 October 2026 | "intensive diabetes therapy"[tiab] AND mortality[ti] AND "type 1 diabetes"[tiab] AND (DCCT[tiab] OR EDIC[tiab]) | contradicting evidence | 1 | |
| Europe PMC | 26 October 2026 | (insulin OR sulfonylurea) AND ("severe hypoglycemia" OR "severe hypoglycaemia") AND (dementia OR "cognitive" OR mortality) AND ("meta-analysis" OR cohort) | supporting evidence | 5468 | |
| PubMed | 26 October 2026 | (insulin[ti] OR "glucose-lowering"[ti]) AND (hypoglycemia[ti] OR hypoglycaemia[ti]) AND (brain[tiab] OR neuroglycopenia[tiab] OR cognitive[tiab]) AND (cohort[tiab] OR meta-analysis[pt]) | supporting evidence | 2 | |
| Europe PMC | 26 October 2026 | (TITLE:insulin) AND ("glucose uptake") AND ("skeletal muscle") AND (clamp OR "insulin action") AND (human OR humans) | contradicting evidence | 3770 | |
| ADA Standards of Care 2026, Sections 6 and 9 (PubMed Central) | 26 October 2026 | Fetched https://pmc.ncbi.nlm.nih.gov/articles/PMC12690178/ ; https://pmc.ncbi.nlm.nih.gov/articles/PMC12690185/; keyword review: ACCORD, hypoglycemia, insulin essential, basal insulin. The diabetesjournals.org DOI landing pages returned HTTP 403; the identical article was read in PubMed Central. | guidelines | 1 | |
| NICE NG17 | 26 October 2026 | Fetched https://www.nice.org.uk/guidance/ng17/chapter/Recommendations; Recommendations chapter: insulin regimens, sick-day rules, ketone monitoring | guidelines | 1 |
Open questions
None that would change the conclusion.
How deeply was this checked?
9 linked studies: 6 checked in full text (4 of them with a structured risk-of-bias assessment), 3 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.
Last scientific review: 26 October 2026
History of the verdict
- 25 October 2026 · Phase 1 · Initial assessment: Mostly false (high)
- 26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: Mostly false (high)
New evidence (DCCT/EDIC mortality, intensive-control meta-analysis, NICE NG17) is consistent with the existing assessment. ACCORD is added explicitly as the strongest evidence for the hypoglycaemia/over-treatment kernel, which is why the verdict stays “Mostly false” rather than “False”.
New sources: I-ODD-108 I-INS-104 I-INS-134
In plain language
Diabetes drugs do not starve the body. Insulin, for example, helps sugar get into muscle cells where it is needed. The real risk is a dose that is too high, causing low blood sugar, which doctors try to prevent by adjusting the dose.
Studies on this claim
Studies supporting the claim (0)
No studies in this group.
Studies contradicting or limiting the claim (4)
-
Review on diabetic ketoacidosis
Dhatariya KK et al.. Nat Rev Dis Primers 2020 · PMID 32409703 · DOI 10.1038/s41572-020-0165-1Narrative reviewindependent cross-checkfull text, structured risk-of-bias assessmentDKA is an emergency that can kill; it is treated with fluids, insulin and salts, and insulin must not be stopped in type 1 diabetes even when not eating.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Epidemiology, pathogenesis, diagnosis and management of DKA
- How was the study done?
Narrative expert review (Nature Reviews Disease Primers)
- How many people, animals or samples were studied?
not applicable; Adults and children with diabetes
- What was actually found?
DKA is diagnosed by high glucose, ketones and acid; it kills <1% when treated in rich countries but up to 26-41% where treatment is lacking; treatment is fluids, insulin and potassium, and insulin must never be stopped in type 1 diabetes even when not eating.
- How large was the observed effect?
not applicable
- What do the results mean in everyday life?
DKA is an emergency.
- What are the study's limitations?
Narrative expert review without systematic methods; one author has research support from insulin makers.
- What does it say about Elawady's specific claim?
- Do the results apply to Germany and Europe?
International.
- What can explicitly not be concluded from this study?
Quantitative estimates.
-
DCCT: better insulin treatment in type 1 diabetes
Diabetes Control and Complications Trial Research Group; Nathan DM et al.. N Engl J Med 1993 · PMID 8366922 · DOI 10.1056/NEJM199309303291401Randomised controlled trialindependent cross-checkabstract checked★ key studyIntensive insulin cut the risk of eye damage by three-quarters and nerve damage by 60%, with more low-sugar episodes.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Does intensive insulin therapy reduce long-term complications in type 1 diabetes?
- How was the study done?
Multicentre RCT (DCCT)
- How many people, animals or samples were studied?
1,441; Insulin-dependent (type 1) diabetes
- What was actually found?
Large reductions in all microvascular complications.
- How large was the observed effect?
Retinopathy -76%
- What do the results mean in everyday life?
Insulin protects eyes, kidneys and nerves in type 1 diabetes.
- What are the study's limitations?
Open-label; Selected young population
- What does it say about Elawady's specific claim?
Contradicts C-INS-07, C-INS-09, C-DIAB-01; shows insulin efficacy and hypoglycaemia cost (C-INS-02 kernel).
- Do the results apply to Germany and Europe?
North American; universally accepted.
- What can explicitly not be concluded from this study?
Effects in type 2 diabetes directly.
-
Long-term survival after intensive insulin treatment in type 1 diabetes
Writing Group for the DCCT/EDIC Research Group et al.. JAMA 2015 · PMID 25562265 · DOI 10.1001/jama.2014.16107Randomised controlled trialindependent cross-checkabstract checked★ key studyPeople who received intensive insulin treatment for about 6.5 years had about one third lower death risk 27 years later.
Intensive insulin therapy reduced mortality over 27 years.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test whether intensive insulin therapy affects long-term survival.
- How was the study done?
Follow-up of a randomised trial.
- How many people, animals or samples were studied?
1,441 young adults with T1D.
- What was actually found?
43 vs 64 deaths; HR 0.67.
- How large was the observed effect?
-109 deaths per 100,000 patient-years.
- What do the results mean in everyday life?
Good insulin treatment helps people with type 1 diabetes live longer.
- What are the study's limitations?
Few deaths; later years observational.
- What does it say about Elawady's specific claim?
Contradicts 'insulin does not treat diabetes'.
- Do the results apply to Germany and Europe?
Applicable to Europe.
- What can explicitly not be concluded from this study?
Cannot separate effects of later care.
-
NICE guideline NG17: Type 1 diabetes in adults: diagnosis and management
National Institute for Health and Care Excellence (NICE). NICE guideline 2015Guideline / position statementindependent cross-checkfull text checked★ key studyUK guideline: insulin is standard for all adults with T1D; DKA treated with IV saline and IV insulin.
Insulin is standard essential therapy; sick-day rules adjust rather than stop insulin.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
National guidance.
- How was the study done?
Evidence-based guideline.
- How many people, animals or samples were studied?
Not applicable.
- What was actually found?
Rec 1.7.1: offer multiple daily injection basal-bolus insulin regimens as the regimen of choice for all adults with T1D. Rec 1.10.1: consider ketone monitoring as part of sick-day rules. Recs 1.10.5-1.10.7: use isotonic saline for fluid replacement in DKA and give intravenous insulin by infusion. Misdiagnosis of T1D as T2D 'could lead to the person not receiving insulin treatment and a subsequent risk of diabetic ketoacidosis'.
- How large was the observed effect?
Not applicable.
- What do the results mean in everyday life?
UK guideline: insulin is standard for all adults with T1D; DKA treated with IV saline and IV insulin.
- What are the study's limitations?
Guideline.
- What does it say about Elawady's specific claim?
Contradicts insulin-free management.
- Do the results apply to Germany and Europe?
UK.
- What can explicitly not be concluded from this study?
Not applicable.
No study in this group is marked as key.
Studies with mixed or unclear results (5)
-
Ketoacidosis with normal blood sugar on SGLT2 drugs
Peters AL et al.. Diabetes Care 2015 · PMID 26078479 · DOI 10.2337/dc15-0843Case series / case reportindependent cross-checkfull text, structured risk-of-bias assessmentSeveral patients developed ketoacidosis with near-normal sugar, so it was recognised late.
Does the study support the specific claim? Yes · Methodological quality: very low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Describe euglycaemic DKA with SGLT2 inhibitors
- How was the study done?
Case series
- How many people, animals or samples were studied?
9 individuals, 13 episodes; Patients with T1D or T2D on SGLT2 inhibitors
- What was actually found?
13 episodes in 9 patients on canagliflozin (7 with off-label type 1 diabetes); glucose often near normal, delaying diagnosis; all recovered with IV fluids and insulin.
- How large was the observed effect?
not applicable
- What do the results mean in everyday life?
Check ketones when unwell on SGLT2 drugs.
- What are the study's limitations?
Incidental case collection, no denominator, mostly off-label type 1 use, all on canagliflozin.
- What does it say about Elawady's specific claim?
- Do the results apply to Germany and Europe?
US.
- What can explicitly not be concluded from this study?
How often this happens; that every SGLT2 inhibitor (e.g. dapagliflozin) carries the same risk (inferred, not shown here).
-
Severe low blood sugar and death in ACCORD
Bonds DE et al.. BMJ 2010 · PMID 20061358 · DOI 10.1136/bmj.b4909Cohort studycited by the Tayebat archivefull text, structured risk-of-bias assessment★ key studyPeople who had severe low-sugar episodes died more often, but this did not explain why the intensive group had more deaths.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Link between severe hypoglycaemia and mortality in ACCORD
- How was the study done?
Retrospective epidemiological analysis within an RCT (ACCORD)
- How many people, animals or samples were studied?
10,194; ACCORD participants with hypoglycaemia assessment
- What was actually found?
Deaths were more common after severe low-sugar episodes (adjusted HR 1.41 and 2.30), but only 1 of 451 deaths was definitely caused by low sugar, and it explained only about 5 of 57 extra deaths in the intensive group.
- How large was the observed effect?
aHR 1.41 (1.03-1.93) intensive arm
- What do the results mean in everyday life?
Severe hypoglycaemia is a danger sign to avoid.
- What are the study's limitations?
Post-hoc observational analysis; Confounding by frailty
- What does it say about Elawady's specific claim?
Supports C-INS-04 (hypoglycaemia is a marker of risk); limits causal interpretation.
- Do the results apply to Germany and Europe?
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
- What can explicitly not be concluded from this study?
That hypoglycaemia caused the ACCORD excess mortality.
-
Severe hypoglycaemia in ADVANCE
Zoungas S et al.. N Engl J Med 2010 · PMID 20925543 · DOI 10.1056/NEJMoa1003795Cohort studycited by the Tayebat archivefull text, structured risk-of-bias assessmentSevere low-sugar episodes were followed by more heart events and deaths, probably partly because frail people get them.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Severe hypoglycaemia and vascular events/death
- How was the study done?
Post-hoc cohort analysis of an RCT (ADVANCE)
- How many people, animals or samples were studied?
11,140; ADVANCE participants with type 2 diabetes
- What was actually found?
aHR 2.69 death.
- How large was the observed effect?
aHR 2.69 (1.97-3.67)
- What do the results mean in everyday life?
Avoid severe hypoglycaemia.
- What are the study's limitations?
Only 231 people had severe hypoglycaemia; links also seen with skin and digestive disease (suggesting frailty); no dose-response; intensive treatment was a sulfonylurea, not insulin; funded by the drug's manufacturer.
- What does it say about Elawady's specific claim?
- Do the results apply to Germany and Europe?
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
- What can explicitly not be concluded from this study?
Causation.
-
Very aggressive blood sugar lowering in high-risk type 2 diabetes
Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743Randomised controlled trialcited by the Tayebat archivefull text checked★ key studyPushing HbA1c below 6% increased deaths by about one-fifth and did not reduce heart attacks or strokes significantly.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Does targeting a normal HbA1c (<6.0%) reduce cardiovascular events in type 2 diabetes with high cardiovascular risk?
- How was the study done?
Multicentre randomised controlled trial (open-label treatment strategies), mean 3.5 years of intensive therapy
- How many people, animals or samples were studied?
10,251; Type 2 diabetes, mean age 62.2, median HbA1c 8.1%, established CVD or additional risk factors
- What was actually found?
More deaths (HR 1.22) and more severe hypoglycaemia with intensive therapy; primary CV outcome not significantly reduced.
- How large was the observed effect?
HR 1.22 (1.01-1.46) all-cause death; HR 0.90 (0.78-1.04) primary outcome
- What do the results mean in everyday life?
Very strict sugar targets are not good for everyone, especially older people with heart disease.
- What are the study's limitations?
Strategy trial: cannot attribute harm to a specific drug; Intensive arm stopped early; High-risk population; not generalisable to early diabetes
- What does it say about Elawady's specific claim?
Core evidence that near-normal HbA1c targets can harm high-risk type 2 patients (C-INS-04).
- Do the results apply to Germany and Europe?
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
- What can explicitly not be concluded from this study?
That insulin specifically caused the deaths, or that lowering high glucose to moderate targets is harmful.
-
Very tight sugar control: fewer heart attacks, more severe low sugars
Control Group (Turnbull FM et al.). Diabetologia 2009 · PMID 19655124 · DOI 10.1007/s00125-009-1470-0Meta-analysisindependent cross-checkabstract checked★ key studyMI -15%, major hypoglycaemia about 2.5 times more frequent; death unchanged.
Confirms the hypoglycaemia kernel; does not support a general cellular 'famine'.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Pool trials of intensive vs standard glucose control.
- How was the study done?
Pre-planned meta-analysis.
- How many people, animals or samples were studied?
27,049 people.
- What was actually found?
Modest MACE reduction; more severe hypoglycaemia; no mortality change.
- How large was the observed effect?
MACE HR 0.91; hypoglycaemia HR 2.48.
- What do the results mean in everyday life?
Over-treating sugar has a real cost; targets should be individual.
- What are the study's limitations?
Older drug strategies.
- What does it say about Elawady's specific claim?
Supports only the hypoglycaemia kernel.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
That glucose-lowering drugs starve cells in general.
No study in this group is marked as key.
Regional context
Germany / EU
European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.
Egypt
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
What applies in my country?
General scientific assessment
Mostly false Mostly false: insulin moves glucose into cells, and the real 'famine' in diabetes comes from a lack of insulin; the true kernel is that over-treatment can cause dangerous low blood sugar, and very aggressive targets increased deaths in the ACCORD trial.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Diabetic ketoacidosis.. Dhatariya KK et al.. Nat Rev Dis Primers 2020 · PMID 32409703 · DOI 10.1038/s41572-020-0165-1
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.. Diabetes Control and Complications Trial Research Group; Nathan DM et al.. N Engl J Med 1993 · PMID 8366922 · DOI 10.1056/NEJM199309303291401
- Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality.. Writing Group for the DCCT/EDIC Research Group et al.. JAMA 2015 · PMID 25562265 · DOI 10.1001/jama.2014.16107
- NICE guideline NG17: Type 1 diabetes in adults: diagnosis and management. National Institute for Health and Care Excellence (NICE). NICE guideline 2015
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.. Peters AL et al.. Diabetes Care 2015 · PMID 26078479 · DOI 10.2337/dc15-0843
- The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.. Bonds DE et al.. BMJ 2010 · PMID 20061358 · DOI 10.1136/bmj.b4909
- Severe hypoglycemia and risks of vascular events and death.. Zoungas S et al.. N Engl J Med 2010 · PMID 20925543 · DOI 10.1056/NEJMoa1003795
- Effects of intensive glucose lowering in type 2 diabetes.. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743
- Intensive glucose control and macrovascular outcomes in type 2 diabetes.. Control Group (Turnbull FM et al.). Diabetologia 2009 · PMID 19655124 · DOI 10.1007/s00125-009-1470-0